Header Logo

Connection

JANKI PATEL to Immunotherapy, Adoptive

Back to Details
This is a "connection" page, showing publications JANKI PATEL has written about Immunotherapy, Adoptive.
JANKI PATEL
Connection Strength
0.148
Immunotherapy, Adoptive
  1. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025 Jan; 26(1):110-122.
    View in: PubMed
    Score: 0.148
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.